Close Menu

NEW YORK (GenomeWeb) – Breaking into markets for nucleic acid testing is not an easy proposition for any startup, but Electronucleics, a company recently founded by University of California, Los Angeles researchers, believes that a device it is developing could satisfy unmet needs for use of an inexpensive, fast, and high-sensitivity device at the point of care.

The nucleic acid diagnostic test they are developing doesn't require complex amplification or expensive optics and, according to the researchers, it could be available as a manufacturing prototype in about a year.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

At a meeting this week, researchers and others discussed the regulatory oversight needed for germline genome editing.

The US Food and Drug Administration has asked questions about Myriad Genetics' GeneSight test, according to Bloomberg.

Researchers report that neutrophil extracellular traps appear to binds gallstones together, according to New Scientist.

In Science this week: approach to infer genotype-by-environment interaction from genetic variants associated with phenotypic variability, and more.